James Harvey

2.6k total citations
44 papers, 1.6k citations indexed

About

James Harvey is a scholar working on Cancer Research, Health, Toxicology and Mutagenesis and Molecular Biology. According to data from OpenAlex, James Harvey has authored 44 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Cancer Research, 18 papers in Health, Toxicology and Mutagenesis and 13 papers in Molecular Biology. Recurrent topics in James Harvey's work include Carcinogens and Genotoxicity Assessment (22 papers), Effects and risks of endocrine disrupting chemicals (8 papers) and Environmental Toxicology and Ecotoxicology (6 papers). James Harvey is often cited by papers focused on Carcinogens and Genotoxicity Assessment (22 papers), Effects and risks of endocrine disrupting chemicals (8 papers) and Environmental Toxicology and Ecotoxicology (6 papers). James Harvey collaborates with scholars based in United Kingdom, United States and Switzerland. James Harvey's co-authors include Véronique Gouverneur, Daniel J. Smart, James M. Parry, Scott P. Simonovich, Christopher R. Jamison, David W. C. MacMillan, Brett P. Lyons, Caroline A. Austin, Anthony M. Lynch and Richard M. Walmsley and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Chemical Communications.

In The Last Decade

James Harvey

44 papers receiving 1.5k citations

Peers

James Harvey
Erwin Eder Germany
Naoto Uramaru Japan
Gregory L. Kedderis United States
Prabhakar D. Devanesan United States
Bernhard H. Monien Germany
B.M. Elliott United Kingdom
Beth Tainer United States
Martin K. Ellis United Kingdom
A. M. Jeffrey United States
Hailing Liu China
Erwin Eder Germany
James Harvey
Citations per year, relative to James Harvey James Harvey (= 1×) peers Erwin Eder

Countries citing papers authored by James Harvey

Since Specialization
Citations

This map shows the geographic impact of James Harvey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Harvey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Harvey more than expected).

Fields of papers citing papers by James Harvey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Harvey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Harvey. The network helps show where James Harvey may publish in the future.

Co-authorship network of co-authors of James Harvey

This figure shows the co-authorship network connecting the top 25 collaborators of James Harvey. A scholar is included among the top collaborators of James Harvey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Harvey. James Harvey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kwon, Deborah Y., Xueying Li, James Harvey, et al.. (2024). CK1δ/ε-mediated TDP-43 phosphorylation contributes to early motor neuron disease toxicity in amyotrophic lateral sclerosis. Acta Neuropathologica Communications. 12(1). 187–187. 2 indexed citations
2.
Bercu, Joel P., Olivier Dirat, Krista L. Dobo, et al.. (2024). N-Nitrosamine drug substance related impurities (NDSRIs) – A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 Da. Regulatory Toxicology and Pharmacology. 154. 105704–105704. 7 indexed citations
3.
Ponting, David J., Andreas Czich, Susan P. Felter, et al.. (2024). Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakes. Regulatory Toxicology and Pharmacology. 156. 105762–105762. 7 indexed citations
4.
Harvey, James, Samir Kapadia, David J. Cohen, et al.. (2024). Trends in Complications Among Patients Undergoing Aortic Valve Replacement in the United States. Journal of the American Heart Association. 13(17). e031461–e031461. 4 indexed citations
5.
Martin, Matthew T., et al.. (2024). Deriving acceptable limits for non-mutagenic impurities in medicinal products – Durational adjustments. Regulatory Toxicology and Pharmacology. 150. 105644–105644. 1 indexed citations
6.
Yang, Hongbin, Amy Pointon, Olga Obrezanova, et al.. (2022). Deriving waveform parameters from calcium transients in human iPSC-derived cardiomyocytes to predict cardiac activity with machine learning. Stem Cell Reports. 17(3). 556–568. 12 indexed citations
7.
Shlevkov, Evgeny, Paramasivam Murugan, Eric Stefan, et al.. (2021). Discovery of small-molecule positive allosteric modulators of Parkin E3 ligase. iScience. 25(1). 103650–103650. 19 indexed citations
8.
Graham, Jessica, Mark W. Powley, Susanne Glowienke, et al.. (2021). Calculating qualified non-mutagenic impurity levels: Harmonization of approaches. Regulatory Toxicology and Pharmacology. 126. 105023–105023. 7 indexed citations
9.
Weidolf, Lars, Thomas Andersson, Joel P. Bercu, et al.. (2019). Qualification of impurities based on metabolite data. Regulatory Toxicology and Pharmacology. 110. 104524–104524. 12 indexed citations
10.
Harvey, James, et al.. (2016). Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development. Regulatory Toxicology and Pharmacology. 84. 116–123. 30 indexed citations
11.
Popelier, Paul L. A., et al.. (2014). Evaluation of aromatic amines with different purities and different solvent vehicles in the Ames test. Regulatory Toxicology and Pharmacology. 71(2). 244–250. 10 indexed citations
12.
Smart, Daniel J., et al.. (2011). Genotoxicity screening via the γH2AX by flow assay. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 715(1-2). 25–31. 89 indexed citations
13.
Pfuhler, Stefan, Marilyn J. Aardema, Carsten Goebel, et al.. (2010). A tiered approach to the use of alternatives to animal testing for the safety assessment of cosmetics: Genotoxicity. A COLIPA analysis. Regulatory Toxicology and Pharmacology. 57(2-3). 315–324. 56 indexed citations
14.
Hastwell, Paul W., Matthew Tate, Nicholas Billinton, et al.. (2009). Analysis of 75 marketed pharmaceuticals using the GADD45a-GFP ‘GreenScreen HC’ genotoxicity assay. Mutagenesis. 24(5). 455–463. 36 indexed citations
15.
Harvey, James, Steven J. Malcolmson, Simon J. Meek, et al.. (2008). Enantioselective Synthesis of P‐Stereogenic Phosphinates and Phosphine Oxides by Molybdenum‐Catalyzed Asymmetric Ring‐Closing Metathesis. Angewandte Chemie International Edition. 48(4). 762–766. 132 indexed citations
16.
17.
Hastwell, Paul W., et al.. (2006). High-specificity and high-sensitivity genotoxicity assessment in a human cell line: Validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 607(2). 160–175. 118 indexed citations
18.
19.
Harvey, James & James M. Parry. (1997). The detectioon of genotoxin-induced DNA adducts in the common mussel Mytilus edulis. Mutagenesis. 12(3). 153–158. 16 indexed citations
20.
Lyons, Brett P., James Harvey, & James M. Parry. (1997). An initial assessment of the genotoxic impact of the Sea Empress oil spill by the measurement of DNA adduct levels in the intertidal teleost Lipophrys pholis. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 390(3). 263–268. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erwin Eder Breakdown of academic impact, for papers by Naoto Uramaru Breakdown of academic impact, for papers by Gregory L. Kedderis Breakdown of academic impact, for papers by Prabhakar D. Devanesan Breakdown of academic impact, for papers by Bernhard H. Monien Breakdown of academic impact, for papers by B.M. Elliott Breakdown of academic impact, for papers by Beth Tainer Breakdown of academic impact, for papers by Martin K. Ellis Breakdown of academic impact, for papers by A. M. Jeffrey Breakdown of academic impact, for papers by Hailing Liu
Rankless by CCL
2026